Tratamento do espasmo facial unilateral com toxina botulínica tipo A

Management of hemifacial spasm with botulinum A toxin

RESUMO

Este estudo retrospectivo apresenta a experiência no tratamento do espasmo facial unilateral com toxina botulínica tipo A. Dezenove pacientes receberam 71 aplicações. O índice de sucesso foi de 94,4%. A duração média do efeito foi de 17,7 (± 7,2) semanas. A incidência de complicações foi de 35,2% e dose dependente, todas elas locais, transitórias e de grau leve a moderado.

Palavras-chave:
Espasmo facial unilateral; Toxina botulínica tipo A

SUMMARY

This retrospective study presents the auhor 's experience in the treatment of the hemifacial spasm whit botulinum toxin type A . Nineteen patients received 71 injections. Success rate was 94.4%. The mean duration of effect after the treatment was 17.7 (± 7.2) weeks. The incidence of complications was 35.2% and dose related. All of them were minar, transitories and restricted to the face.

Key Words:
Hemifacial spasm; Botulinum A toxin

Texto completo disponível apenas em PDF.

• Trabalho realizado no departamento de oftalmologia da Santa Casa de Misericórdia de São Paulo - Fac. Ciências Médicas da Santa Casa de São Paulo.

REFERÊNCIAS BIBLIOGRÁFICAS

• ¹
  Biglan AW, Kim SJ. Management of hemifacial spasm with botulinum A toxin. In: Jankovic, J Hallet M ed. Neurological Disease and Therapy. Therapy with botulinum Toxin. New York: Marcel Dekker 1994;25:353-9.
• ²
  Borodic GE. Hemifacial spasm: Evaluation and management, with emphasis on botulinum toxin therapy. In: Jankovic J & Hallett M ed. Neurological Disease and Therapy. Therapy with botulinum Toxin. New York: Mareei Dekker 1994;25:331-51.
• ³
  Carruthers J, Carruthers A, Bagaric D. Can ptosis incidence be reduced after lid injections of botulinum A exotoxin for blepharospasm and hemifacial spasm. Can J Ophthalmol 1995;30:147.
• ⁴
  Carvalho RRD, Oliveira SV, Rodrigues JRC. Espasmo hemifacial: resultado do tratamento cirúrgico em 14 casos. Arq Neuro-Psiquiat 1973; 31:91-5.
• ⁵
  Dutton JJ, Buckley EG. Long-term results and complications of Botulinum A toxin in the treatment of blepharospasm. Ophthalmol 1988;95:1529-34.
• ⁶
  Frueh BR, Musch DC. Treatment of facial spasm with Botulinum toxin. Ophthalmol 1986;93:917-23.
• ⁷
  Gonnering RS. Blepharospasm and hemifacial spasm. In: Dortzbach, R K ed. Ophthalmic Plastic Surgery. Prevention and Management of Complications. New York: Raven Press ltd.; 1994;8:141-56.
• ⁸
  Guedes MLS, Guedes JS. Inferência sobre médias 111. In Bioestatística para Profissionais de Saúde. Rio de Janeiro: Ao Livro Técnico; 1988;121-36.
• ⁹
  Hallett M , Glocker FX, Deuschl G. Mechanism of action of Botulinum toxin. Ann Neurol 1994;36:449-50.
• ¹⁰
  Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurol 1987;37:616-23.
• ¹¹
  Jannetta PJ, Abbasy M, Maroon JC, Ramos F M, Albin MS. Etiology and definitive microsurgical treatment of hemifacial spasm. J Neurosurg 1977;47:321-8.
• ¹²
  Laskawi R, Ellies M, Drobik C, Bätz A. Botulinum toxin treatment in patients with hemifacial spasm. Eur Arch Otorhinolaryngol 1994;251:271-4.
• ¹³
  Mauriello JA, Coniaris H, Haupt EJ. Use of Botulinum toxin in the treatment of one hundred patients with facial dyskinesias. Ophthalmol 1987;94:976-9.
• ¹⁴
  Osako M, Keltner JL. Botulinum A toxin (Oculinum) in ophthalmology. Surv Ophthalmol 1991;31:28-46.
• ¹⁵
  Price J, O'Day J. Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm. Aust. Nz J Ophthalmol 1994;22:255-60.
• ¹⁶
  Schoenhuber R, Capone L, Pentore R. Benefit of Botulinum toxin A low dosages: Self-estimation by patients suffering from hemifacial spasm and blepharospasm. Neurology., 1995;45:A463.
• ¹⁷
  Scott AB, Kennedy RA., Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 1985;103:347-50, .
• ¹⁸
  Taylor JDN; Kraft SP; Kazdan MS; Flanders M Cadera W, Orton RB. Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. Can J Ophthalmol 1991; 26: 133-8.

Datas de Publicação

• Publicação nesta coleção
  Feb 1998